Report #2827337

Received Feb 20, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: WI
Recovered: Unknown
Vaccinated: Jun 11, 2024
Onset: Jan 1, 2025
Days to onset: 204
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	1	945484	—

Symptoms (2)

Interchange of vaccine productsNo adverse event

Symptom narrative

Received First Dose Heplisav-B, and Second Dose Recombivax; Initial report received on 07-Feb-2025. A pharmacist reported that a 24-year-old female (race, ethnicity not reported) received HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization, then seven months later received a dose of RECOMBIVAX. No medical history or concomitant medications were reported. On 11-Jun-2024, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot # 945484, expiration date 20-Apr-2026, NDC # 43528-0003-05, route, and site not available). In Jan-2025, approximately seven months after having been vaccinated with HEPLISAV-B, the patient received a dose of a hepatitis B vaccine [RECOMBIVAX (lot number and expiration date note reported)]. No side effects were reported. No other information was available. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.